7754
AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy disease; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammato… Read more
7754 (7754) - Net Assets
Latest net assets as of June 2025: NT$510.25 Million TWD
Based on the latest financial reports, 7754 (7754) has net assets worth NT$510.25 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$783.74 Million) and total liabilities (NT$273.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$510.25 Million |
| % of Total Assets | 65.11% |
| Annual Growth Rate | 0.61% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 50.12 |
7754 - Net Assets Trend (2021–2024)
This chart illustrates how 7754's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 7754 (2021–2024)
The table below shows the annual net assets of 7754 from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$662.10 Million | -28.43% |
| 2023-12-31 | NT$925.04 Million | +81.20% |
| 2022-12-31 | NT$510.51 Million | -21.48% |
| 2021-12-31 | NT$650.13 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 7754's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 91985300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$936.92 Million | 141.51% |
| Other Comprehensive Income | NT$64.11 Million | 9.68% |
| Other Components | NT$961.07 Million | 145.16% |
| Total Equity | NT$662.10 Million | 100.00% |
7754 Competitors by Market Cap
The table below lists competitors of 7754 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Unic Technology
TWO:5452
|
$111.91 Million |
|
EQL PHARMA AB
F:7JK
|
$111.94 Million |
|
Community Bank of the Bay
PINK:CBOBA
|
$111.94 Million |
|
Logwin AG
XETRA:TGHN
|
$111.95 Million |
|
Clinica Baviera
MC:CBAV
|
$111.88 Million |
|
Stomil Sanok SA
WAR:SNK
|
$111.80 Million |
|
LCY Technology Corp
TW:4989
|
$111.76 Million |
|
Resources Connection Inc
NASDAQ:RGP
|
$111.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 7754's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 925,040,000 to 662,097,000, a change of -262,943,000 (-28.4%).
- Net loss of 353,986,000 reduced equity.
- New share issuances of 34,839,000 increased equity.
- Other comprehensive income increased equity by 11,329,999.
- Other factors increased equity by 44,874,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-353.99 Million | -53.46% |
| Share Issuances | NT$34.84 Million | +5.26% |
| Other Comprehensive Income | NT$11.33 Million | +1.71% |
| Other Changes | NT$44.87 Million | +6.78% |
| Total Change | NT$- | -28.43% |
Book Value vs Market Value Analysis
This analysis compares 7754's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.45x to 8.98x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$14.38 | NT$64.00 | x |
| 2022-12-31 | NT$7.78 | NT$64.00 | x |
| 2023-12-31 | NT$11.95 | NT$64.00 | x |
| 2024-12-31 | NT$7.13 | NT$64.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 7754 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -53.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -367.02%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.51x
- Recent ROE (-53.46%) is below the historical average (-41.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -30.55% | -13841.46% | 0.00x | 1.03x | NT$-263.64 Million |
| 2022 | -46.36% | -14554.12% | 0.00x | 1.06x | NT$-287.70 Million |
| 2023 | -35.59% | -229.37% | 0.12x | 1.31x | NT$-421.72 Million |
| 2024 | -53.46% | -367.02% | 0.10x | 1.51x | NT$-420.20 Million |
Industry Comparison
This section compares 7754's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,107,525,400
- Average return on equity (ROE) among peers: 2.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 7754 (7754) | NT$510.25 Million | -30.55% | 0.54x | $111.88 Million |
| Synbio Tech Inc. (1295) | $942.97 Million | 12.01% | 1.00x | $21.72K |
| Apex Biotechnology Corp (1733) | $842.42 Million | 19.18% | 0.14x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $875.36 Million | 7.09% | 0.89x | $129.07 Million |
| Panion & BF Biotech Inc (1760) | $278.86 Million | -14.55% | 2.31x | $123.88 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.02 Billion | 5.81% | 0.71x | $42.95 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.16 Billion | 13.75% | 0.60x | $45.13 Million |
| Level Biotechnology (3118) | $498.78 Million | 7.80% | 0.36x | $22.63 Million |
| GenMont Biotech Inc (3164) | $861.62 Million | 3.30% | 0.66x | $31.27 Million |
| Medigen Biotechnology (3176) | $3.18 Billion | -14.68% | 0.53x | $100.57 Million |
| Sagittarius Life Science (3205) | $419.76 Million | -11.56% | 0.24x | $56.40 Million |